Piper Sandler Reaffirms Overweight Rating for TransMedics Group (NASDAQ:TMDX)

Piper Sandler restated their overweight rating on shares of TransMedics Group (NASDAQ:TMDX) in a research report sent to investors on Tuesday, Benzinga reports. Piper Sandler currently has a $180.00 price objective on the stock.

TMDX has been the subject of several other reports. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Robert W. Baird decreased their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday. Oppenheimer decreased their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday. Canaccord Genuity Group decreased their price target on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Needham & Company LLC decreased their price target on shares of TransMedics Group from $208.00 to $109.00 and set a “buy” rating for the company in a research note on Tuesday. One research analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $144.80.

TransMedics Group Price Performance

Shares of NASDAQ TMDX opened at $82.40 on Tuesday. TransMedics Group has a twelve month low of $38.13 and a twelve month high of $177.37. The firm has a fifty day simple moving average of $140.51 and a 200 day simple moving average of $139.29. The company has a market capitalization of $2.77 billion, a PE ratio of 87.66 and a beta of 1.99. The company has a quick ratio of 8.48, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The firm had revenue of $108.76 million for the quarter, compared to the consensus estimate of $115.00 million. During the same period in the prior year, the business earned ($0.12) EPS. TransMedics Group’s quarterly revenue was up 63.7% on a year-over-year basis. On average, sell-side analysts forecast that TransMedics Group will post 1.11 EPS for the current year.

Insider Buying and Selling

In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the transaction, the chief executive officer now directly owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $149.96, for a total transaction of $1,012,230.00. Following the transaction, the director now owns 732 shares in the company, valued at approximately $109,770.72. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 61,247 shares of company stock worth $9,518,181. 7.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Fidelis Capital Partners LLC purchased a new position in TransMedics Group in the first quarter valued at about $35,000. International Assets Investment Management LLC purchased a new position in TransMedics Group in the second quarter valued at about $47,000. USA Financial Formulas purchased a new position in TransMedics Group in the third quarter valued at about $55,000. J.Safra Asset Management Corp boosted its stake in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after acquiring an additional 383 shares during the last quarter. Finally, Signaturefd LLC boosted its stake in TransMedics Group by 26.6% in the second quarter. Signaturefd LLC now owns 443 shares of the company’s stock valued at $67,000 after acquiring an additional 93 shares during the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.